vimarsana.com
Home
Live Updates
FDA Issues Complete Response Letter for neffy® (epinephrine : vimarsana.com
FDA Issues Complete Response Letter for neffy® (epinephrine
Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under...
Related Keywords
United States ,
Laura Oneill ,
Richard Lowenthal ,
Monique Allaire ,
Justin Chakma ,
Strategic Communications ,
Exchange Commission ,
Nasdaq ,
Advisory Committee ,
Drug Administration ,
Pharmaceuticals Inc ,
European Medicines Agency ,
Committee For Medicinal Products Human ,
Complete Response Letter ,
New Drug Application ,
Allergic Reactions ,
Formal Dispute Resolution Request ,
Medicinal Products ,
Human Use ,
Typei Allergic Reactions ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
Investor Contact ,
Media Contact ,
Nasdaq Spry ,
Ars Pharmaceuticals ,
Nc ,
vimarsana.com © 2020. All Rights Reserved.